Compugen vs Wave Life Sciences
Compugen is the larger business, with $72.8m of revenue in fiscal 2025 against $42.7m for Wave Life Sciences (1.7 times as much). Compugen grew faster (161.1% against -60.5%). Compugen kept more of each dollar of sales as profit: a net margin of 48.6% against -478.3%.
| Latest fiscal year | CompugenCGEN, 2025 | Wave Life SciencesWVE, 2025 |
|---|---|---|
| Revenue | $72.8m | $42.7m |
| Revenue growth | 161.1% | -60.5% |
| Net income | $35.3m | −$204m |
| Operating margin | 43.1% | — |
| Net margin | 48.6% | -478.3% |
| Return on equity | 44.8% | -56.2% |
| Free cash flow | $31.3m | −$188m |
| Cash | $90.6m | $602m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 317 |
| Market value | $191m | $707m |
| Price vs our value range | Below our value range | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 12 sales | 6 buys, 46 sales |